Translational Oncology | |
Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand? | |
Emmanuel Seront1  Hélène Houssiau2  | |
[1] Corresponding author.;Department of Medical Oncology, Centre Hospitalier de Jolimont, Rue Ferrer 159, 7100 Haine Saint Paul, Belgium; | |
关键词: Urothelial carcinoma; Immune checkpoint inhibitors; Maintenance strategy; PD-L1; Platinum-based strategy; | |
DOI : | |
来源: DOAJ |
【 摘 要 】
Immune checkpoint inhibitors (ICIs) have significantly improved the outcome of patients with metastatic urothelial cancer (mUC). If these agents were first used in monotherapy after failure of platinum-based chemotherapy, new strategies have been evaluated in the last years, including association of ICIs, ICI plus chemotherapy association or maintenance therapy. This maintenance concept allows a better management of mUC, which is particularly interesting in cisplatin-ineligible patients.This paper aims to review the current knowledge of ICIs in urothelial carcinoma as well as the new indications of these agents in mUC.
【 授权许可】
Unknown